Professor and Chairman Department of Biochemistry and Molecular Biology, College of Medicine, Stokes-Shackelford Professor, Associate Director for Education and Training, Fred & Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer
Professor and Chairman, Biochemistry and Molecular Biology, Distinguished Helen Freytag Professor of Cancer Biology, Associate Director for Training and Education, Eppley Cancer Institute
Ph.D., NDRI (Kurukshetra Univ.), INDIA, 1983
Student research opportunities in my lab:
Medical students, summer research
Undergraduate students, summer research
Primary Research/Clinical Interests/Expertise:
Tumor-associated genes; cancer diagnostics, cancer vaccines; monoclonal antibodies, genetic engineering of antibodies
Tumor-associated Genes: Identification, Structure/Function Analysis, and Evaluation as Targets for Diagnosis/Therapy
The overall goals of our laboratory are to study the molecular mechanisms of neoplastic transformation, differentiation, and altered-growth in human pancreatic, ovarian and prostate tumors. Normal cell proliferation is under the intrinsic control of growth-promoting proto-oncogenes and growth-constraining anti-oncogenes.
Specifically, we are defining multifaceted roles of tumor associated antigens (MUC4 and PD2/hPaf1) in the pathogenesis of pancreatic, breast, ovarian and prostate cancers.
We cloned the full-length MUC4 cDNA (28 Kb) from human pancreatic tumor cDNA libraries and established its complete genomic organization (25 exons/introns over 100 kb) and expression profiles (Figure 1). Our studies have demonstrated the specific and differential expression of MUC4 in many cancers compared to normal tissues. Furthermore, using a MUC4-specific MAb generated in our laboratory, we showed that de novo expression of MUC4 is observed in precancerous pancreatic intraepithelial neoplasias (PanINs) and its expression increases progressively with the development of PC. These results were further confirmed in collaboration with investigators at University of California at San Francisco and University of Alabama. Notably, the overexpression of MUC4 is also associated with a poor prognosis for patients with PC. In multiple in-vitro and in-vivo studies, we have shown that the aberrant expression of MUC4 in PC results from diverse regulatory mechanisms.
MUC4 is a large-sized membrane-anchored glycoprotein. The size of the MUC4 apomucin is 930 kDa and it is comprised of a 850 kDa mucin-type subunit (MUC4α) and an 80 kDa membrane-tethered subunit (MUC4β) (Figure 2). Several allelic and splice-variants of MUC4 are also reported. MUC4a possesses three important domains [TR (tandem-repeat), NIDO (nidogen-like) and AMOP (adhesion-associated domain in MUC4 and other proteins)], while MUC4b has three EGF-like domains and a short cytoplasmic tail. The MUC4α-subunit is thought to participate in adhesion and anti-adhesion mechanisms, while a role of MUC4β in cell signaling is proposed. In our recent studies, using ‘loss' and ‘gain' of function approaches, we have shown a direct association of the MUC4 mucin with the metastatic PC phenotype and provided experimental evidence for a functional role of MUC4 in altered growth and invasive properties of tumor cells. MUC4 was significantly associated with motility/invasion and anti-adhesive properties of pancreatic tumor cells. Interestingly, our study also revealed a correlative decrease in HER2 expression upon downregulation of MUC4. We have observed that both MUC4 and HER2 co-localize with each other at the cell surface and in the cytoplasm of PC cells. The physical association between MUC4 and HER2 was confirmed by coimmunoprecipitation and in vivo co-clustering. Our subsequent studies have indicated that MUC4-mediated regulation of HER2 may occur by post-transcriptional mechanism(s). In other studies, we have observed that MUC4 expression in NIH3T3 mouse fibroblast cells leads to the oncogenic transformation of these cells. Taken together, the structural attributes of MUC4, its aberrant expression and functional role in the tumorigenicity and metastasis of cancer cells provide experimental evidence for the multifaceted roles of MUC4 in the progression cancer. Under normal conditions, MUC4 is localized at the apical surface of the epithelial cells. However, during the course of cancer progression, tumor cells lose polarity, allowing ubiquitous cell surface expression of MUC4 and its subsequent interaction with novel partner(s) such as HER2. Association of MUC4 with HER2 may protect disseminated tumor cell from anoikis via HER2-mediated mechanisms, thus facilitating the primary tumor growth. Overexpression of MUC4 on the cell surface further disrupts the interaction between adhesion molecules which may facilitate the motility and invasion properties of tumor cells. The process of metastasis may be further assisted by adhesion of MUC4 on endothelial cells by interacting with glycoproteins (Galectin-3 or selectins).
Currently, we are working on:
- Defining the mechanism(s) responsible for MUC4-mediated regulation of HER2 in pancreatic cancer cells.
- Determining the molecular mechanisms by which MUC4 contributes to tumor growth and metastasis.
- Investigating the co-operative action of MUC4 in combination with other defined oncogenic mutations, in the early development of pancreatic cancer.
In addition to these goals, MUC4 is being explored as a maker for early diagnosis and target for active and passive therapy in many cancers in our laboratory. In addition to MUC4, other projects are:
- Genetically engineered multivalent single chain antibody constructs for cancer therapy. This proposal is aimed to generate, characterize, increase production and affinity of multivalent antibody constructs reactive with the tumor associated Sialyl-Tn antigen present on TAG-72 and to determine the utility of these specific antibodies for the diagnosis and treatment of cancer. The phage display technology is being used for the development of new tumor-specific human monoclonal antibodies.
- Understanding the dysregulation of PD2/hPaf 1 and hPAF1 complex in cancers.
- Molecular and biochemical studies on PDF/MIC-1.
Total 327 Publications (selected shown below from last three years):
Mimeault M and Batra SK Molecular Biomarkers of Cancer Stem/Progenitor Cells Associated with Progression, Metastases and Treatment Resistance of Aggressive Cancers. Cancer Epidemiol Biomarkers 23(2):234-54, 2014.
Momi, N, Kaur S, Rachagani S, Ganti, AK, Are C and Batra SK Smoking and MicroRNA Dysregulation: A Cancerous Combination Trends in Molecular Medicine, 20, 36-47, 2014
Kaur S, Sharma N, Krishn SR, Lakshaman I, Rachagani S, Baine MJ, Smith LM, Lele SM, Sasson AR, Guha S, Mallya K, Anderson JM, Hollingsworth MA, Batra SK. MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer. Clinical Cancer Research 20(3):688-700, 2014.
Mimeault M and Batra SK. Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Molecular Aspects of Medicine, S0098-2997(13)00059-9, 2013.
Ponnusamy M.P, Seshacharyulu P, Lakshmanan I, Vaz A, Chugh S and Batra. S.K. Emerging role of mucins for epithelial to mesenchymal transition. Current Cancer Drug Targets, 13(9):945-56,2013
Torres, M.P, Rachagani, S., Souchek, J.J., Mallya, K., Johansson, S.L., and Batra, S.K. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy. PLoS One. 8(11), e80580. 2013
Kaur, S, Kumar S. Momi N, Sasson AR, and Batra SK Mucins in pancreatic cancer and its microenvironment. Nature Reviews Gastroenterology & Hepatology, 10(10):607-20, 2013
Shimizu T, Torres MP, Chakraborty S, Souchek JJ, Rachagani S, Kaur S, Macha M, Ganti AK, Hauke RJ, Batra SK. Holy Basil leaf-extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: Potential role in therapy. Cancer Letters, 336(2):270-80, 2013
Pandey P, Seshacharyulu P, Das S, RachaganiS, Ponnusamy MP, Yan Y, JohanssonSL, Datta K, Lin MF and Batra SK. Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. British J. Cancer, 108(12):2590-600, 2013.
Momi N, Poonusamy, Kaur S, Rachagani S, MP, Kunigal, S.S, Chellappan Sand Batra SK Nicotine up-regulates MUC4 mucin via α7 nicotinic acetylcholine receptor and JAK2/STAT3 signaling cascade. Oncogene, 32(11):1384-95, 2013
Jain M, Gupta S, Kaur S, Ponnusamy, MP and Batra SK. Emerging Trends for Radioimmunotherapy in Solid Tumors. Cancer Biotherapy and Radiopharmaceuticals, 28(9):639-50, 2013.
Majhi PD, Lakshmanan I, Ponnusamy MP, Jain M, Das D, Kaur S, Shimizu ST, West WW, Johansson SL, Smith LM, Yu, . Rolle CE, Sharm P, Carey GB, Batra SK and Ganti AP. Pathobiological implications of MUC4 in non-small-cell lung cancer. Journal of Thoracic Oncology, 8(4):398-407, 2013
Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R, Felsher DW, Dimaio DJ, Hollingsworth MA, Morris JP 4th, Hebrok M, Witkiewicz AK, Brody JR, Rui H, and Wagner KU. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Research 73(6):1821-1830, 2013.
Kaur S, Baine MJ, Guha S, Ochi N, Chakraborty S, Mallya K, Thomas C, Crook J, Wallace MB, Woodward TA, Jain M, Singh S, Sasson AR, Skinner V, Raimondo M, and Batra SK. Neutrophil Gelatinase-Associated Lipocalin, Macrophage Inhibitory Cytokine 1, and Carbohydrate Antigen 19-9 in Pancreatic Juice: Pathobiologic Implications in Diagnosing Benign and Malignant Disease of the Pancreas. Pancreas,42(3):494-501, 2013.
Mimeault M., Johansson S.L., Batra SK Marked improvement of anticarcinogenic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by down-regulating macrophage inhibitory cytokine-1. British Journal of Cancer 108(5):1079-91, 2013.
Mukhopadhyay P, Lakshmanan I, Ponnusamy MP, Chakraborty S, Jain M, Pai P, Smith LM, Subodh LM, and Batra SK MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells. PLoSOne, 8(2):e54455 2013.
Mimeault, Mand Batra SK Emergence of Zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials. Drug Discovery Today 18(3-4):128-40, 2013.
Mimeault M and Batra SK Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. Journal of Cellular and Molecular Medicine,17(1):30-54, 2013.
Kaur S, ShimizuT. Baine M.J, Kumar S and Batra SK Immunohistochemistry of Pancreatic Neoplasia. Pancreatic Cancer: Methods and Protocols (Methods in Molecular Biology), 980:29-42, 2013.
Momi N, Kaur S, Krishan SR and Batra SK. Discovering the route from inflammation to pancreatic cancer. Minerva Gastroenterology Dietol 58:283-97, 2012.
Rachagani S, Torres MP, Kumar S, Haridas D, Baine M, Macha MA, Kaur S, Ponnusamy MP, Dey P, Seshacharyulu P, Johansson SL, Jain M, Wagner KU, and Batra SK. Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. J. Hematol Oncol. 5:68, 2012.
Hamada, T, Nomura, M., Kamikawa, Y, Yamada, N, Batra S.K, Yonezawa, S, and Sugihara K. Aberrant Expression of MUC1 Mucin is Associated with Tumor Aggressiveness, Subsequent Lymph Node Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. Cancer 118(21):5251-64, 2012.
Dey P, Rachagani S, Chakraborty S, Singh PK, Zhao X, Gurumurthy CB, Anderson JM, Lele S, Hollingsworth MA, Band V and Batra SK Overexpression of Ecdysoneless (Ecd) in Pancreatic Cancer and its Role in Oncogenesis by Regulating Glycolysis. Clinical Cancer Research, 18(22):6188-98, 2012.
Tamura Y, Higashi M, Kitamoto S, Yokoyama S, Osako M,Horinouch M, Shimizu T, Tabata M, Batra S.K, Goto M and Yonezawa S. MUC4 and MUC1 Expression in Adenocarcinoma of the Stomach Correlates with Vessel Invasion and Lymph Node Metastasis: An Immunohistochemical Study of Early Gastric Cancer. PLosOne, 7(11):e49251, 2012.
Kaur S, Baine MJ, Jain M, Sasson AR, and Batra SK. Early diagnosis of pancreatic cancer: Challenges and New Developments. Clinical Biomarkers, 6(5):597-612, 2012.
RachaganiS, Macha MA, Ponnusamy MP, Haridas D, Kaur S, Jain M, and Batra SK MUC4 potentiates invasive and metastatic behavior of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1 (FGFR1). Carcinogenesis,33(10):1953-64,2012.
Kitamoto S, Yokoyama S, Higashi M, Yamada N, Shyuichiro M, Takao S, Batra S.K and Yonezawa S Upregulation of MUC17 by HIF1alpha-mediated Hypoxic Response and Requires a Methylaiton-free Hypoxia Responsible Element in Human Pancreatic Cancer. PLoS One, 7(9):e44108, 2012.
267. Momi N, Kaur S., Poonusamy, Kumar S, Wittel UA and Batra SK Interplay Between Smoking-induced Genotoxicity and Altered Signaling in Pancreatic Carcinogenesis. Carcinogenesis 33(9):1617-28, 2012. PMID22623649/PMC3514894
Hamada T, Wakamatsu T Miyahara M, Nagata S, Nomura M, Kamikawa Y, Yamada N, Batra SK., Yonezawa S, and Sugihara, K. MUC4: a novel prognostic factor of oral squamous cell carcinoma International J. Cancer, 130(8):1768-76, 2012
Senapati, S, Gnanapragassam VS, Moniaux N, Momi N, and Batra SK. Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. Oncogene, 31(28):3346-56, 2012.
Baine M J, Menning M, Smith L, Mallya K, Kaur S, Rachagani S, Chakraborty S, Sasson A R,. Brand R E, and Batra S K. Differential expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer. Cancer Biomarkers, 11, 1-14 2012, Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R.. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Research Treatment, 134(2):583-93, 2012.
Sadanandam, A, Sidhu, SS, Wullschleger S, Singh S, Varney, ML., Yang, CS, Ashor A, Batra S.K and Singh R.K. Secreted Semaphorin 5A mediates Reduced Pancreatic Tumor Burden but Enhanced Micrometastasis and Endothelial Cell Proliferation. British J. Cancer, 107(3):501-7, 2012.
Torres MP, Rachagani S, Purohit V, Pandey P, Joshi S, Moore ED, Johansson SL, Singh PK, Ganti AK, and Batra SK. Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Letters 323(1):29-40, 2012.
Kunigal S, Ponnusamy MP, Momi N, Batra SK and Chellappan SP. Nicotine, IFN-gamma and retinoic acid mediated induction of MUC4 in pancreatic cancer requires E2F1 and STAT-1 transcription factors and utilize different signaling cascades. Molecular Cancer 11(1):24, 2012.
Mimeault M, Johansson SL, and Batra SK Pathobiological Implications of the Expression of EGFR, pAkt, NF-kappaB and MIC-1 in Prostate cancer Stem Cells and their Progenies PLoS One, 7(2):e31919, 2012.
Tarang S, Kumar S and Batra SK Mucins and Toll-Like Receptors: Kith and Kin in infection and cancer. Cancer Letters 321(2):110-9, 2012.
Chakraboty S., Kaur S, Guha S., and Batra SK Multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and Cancer. BBA Reviews in Cancer, 1826(1):129-169, 2012.
Kelsey L, Katoch P, Johnson, K.E, Batra S.K, and Mehta PP. Retinoids regulate the formation and degradation of GAP junctions in androgen-responsive human prostate cancer cells. PLoS One, 7(4):e32846, 2012.
Mimeault M., and Batra SK Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World Journal of Clinical Oncology,3(3):32-42,2012.
Torres M.P, Chakraborty S, Souchek J, and Batra SK. Mucin-based Targeted Pancreatic Cancer Therapy. Current Pharmaceutical Design,18(17):2472-81,2012.
Lakshmanan I, Ponnusamy M.P, Das S, Chakraborty S, Haridas D., Mukhopadhyay P, Lele S.M and Batra SK MUC16 Induced Rapid G2/M Transition via Interaction with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene,31(7):805-17,2012. PMID21785467/PMC3288594
Higashi M, Yamada N, Yokoyama S, Kitamoto S, Tabata K, Koriyama C, Batra SK, and Yonezawa S. Pathobiological implications of MUC16/CA125 expression in intrahepatic Cholangiocarcinoma-Mass Forming Type. Pathobiology, 79(2):101-106, 2012
Seshacharyulu,P, Ponnusamy, MP, Haridas, D, Jain, M, Ganti A.K and Batra SK Targeting the EGFR signaling pathway in cancer therapy. Expert Opinions on Therapeutic Targets, 16, 15-31, 2012.
Kaur S, Venktaraman G, Jain M, Senapati S, Garg P.K and Batra SK Recent advances in antibody-based imaging for solid tumor. Cancer Letters 315, 97-111, 2012.
Haridas D, Chakraborty S, Ponnusamy MP, Lakshmanan I, Rachagani S, Cruz E, Kumar S, Das S, Lele SM, Anderson JM, Wittel UA, Hollingsworth MA, and Batra SK Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One, 6(10), e26839, 2011.
Mimeault M.,and Batra SK Recent insight on deregulated gene products in prostate cancer- and metastasis-initiating cells and novel promising multitargeted therapies. Molecular Medicine, 17(9-10):949-64, 2011. PMID21607288/PMC3188882
Tong Z, Chakraborty S, Sung B, Koolwal P, Kaur S, Aggarwal BB, Mani SA, Bresalier RS, Batra SK, and Guha S. Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. Cancer, 117 (11), 2408-2418, 2011.
Dey P, Poonusamy, MP., Deb, S and Batra SK. Human RNA Polymerase II-Association Factor 1 (hPaf1/PD2) Regulates Histone Methylation and Chromatin Remodeling in Pancreatic Cancer. PLoS One 6(10):e26926, 2011.
Mimeault M., and Batra SK Animal models of prostate carcinogenesis underlining the critical implication of prostatic stem progenitor cells. BBA Reviews on Cancer,1816(1):25-37, 2011.
Mimeault M., and Batra SK Pivotal roles of the wild-type EGFR, EGFRVIII mutant and hedgehog cascades in brain tumor-initiating cells and their progenies and new targeted therapies. Brain Pathology,21(5):479-500, 2011
Jain M., Venkatraman G, Moniaux N., Kaur S., Kumar S., Chakraborty S., Varshney G.C and Batra SK Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer. PLoS ONE, 6(8), e23344, 2011.
Baine MJ, Sahaq F, Lin C, Chakraborty S, and Batra SK. Marital status and survival in pancreatic cancer patients: a SEER based retrospective analysis. PLoS One, 6(6):e21052, 2011.
Resta-Lenert, S., Das S., Batra SK and Ho, S.B. MUC17 protects intestinal epithelial cells from enteroinvasive E.coli infection by promoting epithelial barrier integrity. Am J Physiology, 300(6):G1144-55, 2011.
Ponnusamy, M.P., Seshacharyulu P, Vaz A, Dey, P., and Batra SK MUC4 stabilizes HER2 expression and maintains the cancer stem cell populations in ovarian cancer cells. J. Ovarian Research, 4(1):7, 2011. PMID21521521/PMC3111401
Chakraborty S, Tarantolo SR, Treves J, Sambol D, Hauke RJ, Batra SK. Progressive Multifocal Leukoencephalopathy in an HIV-Negative Patient with Small Lymphocytic Leukemia following treatment with Rituximab. Case Reports in Oncology 4,136–142, 2011.
Wang G, Lipert RJ, Jain M., Kaur S., Chakraboty, S, Torres M., Batra SK, Brand RE and Porter M. Detection of the potential pancreatic cancer marker MUC4 in serum using Surface-Enhanced Raman Scattering (SERS). Analytical Chemistry 83(7):2554-61, 2011.
Rachagani S, SenapatiS, Chakraborty S, PonnusamyMP, KumarS, SmithL.M, JainM and Batra SK. Activated KrasG12D associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. British Journal of Cancer,104(6):1038-48, 2011.
Mimeault M, and Batra SK Recent progress and related patents on the applications of bone marrow-derived stem/progenitor cells in regenerative medicine and cancer therapies. Recent Patents on Regenerative Medicine, 1, 42-59, 2011.
Baine M, Chakraborty S, Smith L, Mallya K, Sasson A, Brand R and Batra SK Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility.. PLoS One, 10;6(2):e17014, 2011.
Mukhopadhyay, P; Chakraborty, S, Ponnusamy, M.P., Lakshmanan, I., Jain, M. and Batra SK Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. BBA Reviews on Cancer,1815(2):224-240,2011.
Kitamoto S, Yamada N, Yokoyama S, Houjou I, Higashi M., GotoM., Batra SK., Yonezawa S. MUC17 gene expression is under control of epigenetic modifications in cancer cells. Glycobiology,21(2):247-56, 2011.
Senapati S., Chaturvedi P., Chaney W. Subhankar Chakraborty, Vinayaga S. Gnanapragassam, Aaron R. Sasson and Batra SK A novel interaction of galectin-3 with MUC4 in pancreatic adenocarcinoma: potential pathological implication, Clinical Cancer Research, 17(2):267-74, 2011
Chakraborty S., Baine M, Sasson AR., and Batra S.K Current Status of diagnosis of lethal pancreatic cancer. BBA Reviews on Cancer, 1815, 44-65, 2011
Current Grants and Contracts:
Principal Investigator: Surinder K. Batra
Title: Pancreatic tumor microenvironment network
Dates of the entire project 9/26/011-7/31/16
NIH RO3 CA167342 (NIH)
Principal Investigator: Surinder K. Batra
Title:Targeting MUC4 for chemosensitization of pancreatic cancer
Dates of entire project 7/01/012-6/30/14
RO1, CA 138791-03 (NIH)
Principal Investigator: Surinder K. Batra
Title:Novel Deregulated Genes in the Etiology and Progression of Human Prostate Cancer
Dates of the entire project 5/01/010-2/28/15
RO1, CA133774-5 (NIH)
Principal Investigator: Surinder K. Batra
Title: Smoking and pancreatic cancer
Dates of entire project 3/01/08-12/31/13
NIH SPOREP50 CA127297-05
Project (#3) Leader: Surinder K. Batra
Title of Project:Biological Marker(s) in the Diagnosis of Pancreatic Cancer
Program Director: Michael Hollingsworth
Dates of entire project 09/05/08-06/30/14
Principal Investigators: Michael Hollingsworth and Surinder K. Batra
Title: Early diagnosis of pancreatic cancer.
Dates of entire project 9/13/10-6/30/15
Principal Investigator: ich Bro
Title: Nebraska Center for nanomedicine
Role on the project: Co-investigator/Mentor
Dates of entire project 10/01/08-09/30/18